BBI503
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastrointestinal Stromal Tumors
Conditions
Gastrointestinal Stromal Tumors
Trial Timeline
Mar 13, 2017 → Jul 25, 2017
NCT ID
NCT02232620About BBI503
BBI503 is a phase 2 stage product being developed by Sumitomo Pharma for Gastrointestinal Stromal Tumors. The current trial status is terminated. This product is registered under clinical trial identifier NCT02232620. Target conditions include Gastrointestinal Stromal Tumors.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02232620 | Phase 2 | Terminated |
| NCT02232646 | Phase 2 | Withdrawn |
| NCT02432690 | Phase 2 | Terminated |
| NCT02232633 | Phase 2 | Completed |
| NCT01781455 | Phase 1 | Completed |
Competing Products
20 competing products in Gastrointestinal Stromal Tumors